|Systematic (IUPAC) name|
|(3R)-N-methoxyquinuclidine-3-carboximidoyl cyanide hydrochloride|
|Legal status||Never marketed|
|Mol. mass||193.12 g/mol|
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease. It made it to phase III clinical trials before being discontinued due to poor results.
- Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics 283 (3): 1059–68. PMID 9399977.
Read in another language
This page is available in 1 language